Charles Schwab
CTSO icon

Charles Schwab’s Cytosorbents Corp CTSO Stock Holding History

Charles Schwab’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-800
Closed -$17.8K – 3479
2023
Q4 		$17.8K Hold
800
– – ﹤0.01% 3494
2023
Q3 		$30.1K Sell
800
-25
-3% -$1.44K ﹤0.01% 3468
2023
Q2 		$59.2K Buy
825
+25
+3% +$1.58K ﹤0.01% 3399
2023
Q1 		$53.9K Hold
800
– – ﹤0.01% 3337
2022
Q4 		$24.8K Hold
800
– – ﹤0.01% 3476
2022
Q3 		$22K Hold
800
– – ﹤0.01% 3472
2022
Q2 		$36K Sell
800
-4,485
-85% -$206K ﹤0.01% 3437
2022
Q1 		$338K Buy
5,285
+28
+0.5% +$2.01K ﹤0.01% 3191
2021
Q4 		$441K Buy
5,257
+113
+2% +$12.7K ﹤0.01% 3185
2021
Q3 		$836K Sell
5,144
-26
-0.5% -$4.22K ﹤0.01% 2935
2021
Q2 		$781K Sell
5,170
-50
-1% -$8.43K ﹤0.01% 3016
2021
Q1 		$907K Buy
5,220
+156
+3% +$29.7K ﹤0.01% 2893
2020
Q4 		$808K Buy
5,064
+314
+7% +$52.6K ﹤0.01% 2836
2020
Q3 		$758K Buy
4,750
+546
+13% +$98.5K ﹤0.01% 2747
2020
Q2 		$833K Buy
4,204
+145
+4% +$26.6K ﹤0.01% 2681
2020
Q1 		$628K Hold
4,059
– – ﹤0.01% 2638
2019
Q4 		$313K Sell
4,059
-284
-7% -$24.8K ﹤0.01% 2963
2019
Q3 		$437K Buy
4,343
+279
+7% +$32.5K ﹤0.01% 2854
2019
Q2 		$538K Buy
4,064
+972
+31% +$134K ﹤0.01% 2776
2019
Q1 		$469K Sell
3,092
-66
-2% -$10.3K ﹤0.01% 2784
2018
Q4 		$511K Buy
3,158
+37
+1% +$7.35K ﹤0.01% 2761
2018
Q3 		$806K Buy
3,121
+131
+4% +$32.8K ﹤0.01% 2691
2018
Q2 		$682K Buy
+2,990
New +$566K ﹤0.01% 2696

Other funds holding CTSO

Avenir Corporation
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Granahan Investment Management
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Charles Schwab's CTSO Position: Q1 2024 in Review

Charles Schwab sold out of Cytosorbents Corp (CTSO) in Q1 2024, closing a stake of 800 shares — an estimated $17.8K sold.

Charles Schwab first reported a position in CTSO in Q2 2018 and held it in 23 quarters. The position peaked at $907K in Q1 2021. 48 funds tracked by Wall St. Rank hold CTSO as of Q1 2024.

  • Charles Schwab reported no remaining Cytosorbents Corp position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 800 Cytosorbents Corp shares in Q1 2024, an estimated $17.8K.
  • Charles Schwab first reported a position in Cytosorbents Corp in Q2 2018 and held it in 23 quarters.
  • Charles Schwab's Cytosorbents Corp position peaked at $907K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.